Outcomes of osimertinib in non-small-cell lung cancer and acquired EGFR Thr790Met mutation

  • The Lancet Pneumology

    没有评分

Future development strategies for osimertinib may be dictated by difference in resistance mechanisms

Future development strategies for osimertinib may be dictated by difference in resistance mechanisms

Background

Osimertinib is approved for the treatment of non-small-cell lung cancer in patients who develop the EGFR Thr790Met mutation after treatment with epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs). We assessed outcomes in patients with non-small-cell lung cancer and the EGFR Thr790Met mutation who were treated with osimertinib, a third-generation EGFR TKI, after previous treatment failure with one or more other EGFR TKIs.

Methods

Eligible patients had been enrolled at one centre in the AURA study, had shown resistance to a previous EGFR TKI, and had EGFR activating mutations and acquired Thr790Met mutation detectable in tumour tissue or plasma. Patients took 20–240 mg osimertinib per day until disease progression or development of intolerable sideeffects. Plasma samples were collected every 6 weeks and tumour tissue biopsy was done at study entry and was optional after disease progression. We tested samples for resistance mechanisms, including EGFR-activating, Thr790Met, and Cys797Ser mutations, and assessed associations with overall survival, progression-free survival, and survival after disease progression.

Findings

Of 71 patients enrolled in AURA, 53 were eligible for this analysis. Median progression-free survival was 11.1 months (95% CI 8.4–13.9) and overall survival was 16.9 months (11.7–29.1). 47 patients had disease progression. Median overall survival after osimertinib progression was 5.4 months (95% CI 4.1–10.0). Plasma samples were available for 40 patients after disease progression. 12 (30%) of these had the Thr790Met mutation (four of whom also had Cys797Ser mutations). Patients without detectable EGFR-activating mutations in plasma before treatment had the best overall and post-progression survival (22.4 months, 95% CI 15.6–not reached, and 10.8 months, 7.2–not reached, respectively). Loss of the Thr790Met mutation but presence of EGFR-activating mutations in plasma were associated with the shortest progression-free survival (median 2.6 months, 95% CI 1.3–not reached). In 22 postprogression tumour samples, we found one squamous cell and two small-cell transformations. We detected Thr790Met in nine (50%) of 18 samples, Cys797Ser in two (17%) of 12, cMET amplification in five (50%) of ten, BRAF mutation in one (8%) of 13, and KRAS mutation in one (8%) of 13.

Interpretation

Heterogeneous resistance mechanisms developed in patients receiving osimertinib. Differences in resistance mechanisms might dictate future development strategies for osimertinib in clinical trials.

Funding

AstraZeneca, Taiwan Ministry of Science and Technology.

返回顶部

免责申明

© 2015 Elsevier Ltd. All rights reserved. This journal and the individual contributions contained in it are protected under copyright by Elsevier Ltd, and the following terms and conditions apply to their use. The Lancet is a trade mark of RELX Intellectual Properties SA, used under license.No responsibility is assumed by Elsevier for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. 
 
The translation has been undertaken by Transperfect at its sole responsibility. No responsibility is assumed by Elsevier in relation to the translation or for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.
 
未经许可,严禁转载!